MannKind Corporation Share Price Nasdaq
Stocks
US56400P2011
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| Market Cap | 98Cr 88Cr 82Cr 75Cr 140.02Cr 9.33TCr 140.89Cr 987.51Cr 385.59Cr 4.84TCr 368.19Cr 360.22Cr 16TCr | P/E 2026 * |
-16.6x | P/E 2027 * | 1,220x |
|---|---|---|---|---|---|
| Enterprise Value | 98Cr 88Cr 82Cr 75Cr 140.02Cr 9.33TCr 140.89Cr 987.51Cr 385.59Cr 4.84TCr 368.19Cr 360.22Cr 16TCr | EV / Sales 2026 * |
2.21x | EV / Sales 2027 * | 1.94x |
| Free-Float |
98.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: MannKind Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Castagna
CEO | Chief Executive Officer | 49 | 25/05/2017 |
| Director of Finance/CFO | 50 | 22/04/2024 | |
Ajay Ahuja
CTO | Chief Tech/Sci/R&D Officer | - | 29/09/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Ronald Consiglio
BRD | Director/Board Member | 82 | 01/10/2003 |
Michael Friedman
BRD | Director/Board Member | 82 | 01/12/2003 |
James Shannon
CHM | Chairman | 69 | 09/12/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.01% | -7.86% | +54.60% | +70.97% | 7.04TCr | |
| +3.84% | -11.02% | +8.59% | +58.77% | 5.03TCr | |
| +3.35% | +1.42% | +11.85% | +37.39% | 4.75TCr | |
| +0.77% | +1.48% | +27.92% | +31.64% | 4.29TCr | |
| +2.20% | -3.97% | +306.08% | +465.33% | 4.04TCr | |
| +1.37% | -2.93% | +10.10% | +103.14% | 3.97TCr | |
| +0.06% | -1.43% | +10.47% | +43.27% | 3.06TCr | |
| -2.95% | -14.09% | +37.94% | +1.30% | 2.68TCr | |
| +0.13% | -6.20% | -12.93% | -7.87% | 2.24TCr | |
| Average | +0.73% | -5.58% | +50.51% | +89.33% | 4.12TCr | |
| Weighted average by Cap. | +0.82% | -5.44% | +53.50% | +94.77% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 44Cr 40Cr 37Cr 34Cr 63Cr 4.23TCr 64Cr 447.8Cr 174.85Cr 2.2TCr 166.96Cr 163.35Cr 7.06TCr | 51Cr 45Cr 42Cr 38Cr 72Cr 4.81TCr 73Cr 509.18Cr 198.82Cr 2.5TCr 189.85Cr 185.74Cr 8.03TCr |
| Net income | -5.76Cr -5.18Cr -4.83Cr -4.38Cr -8.22Cr -547.82Cr -8.27Cr -58Cr -23Cr -284.32Cr -22Cr -21Cr -914.45Cr | 10.53L 9L 9L 8L 15.04L 10Cr 15.13L 1.06Cr 41.41L 5.2Cr 39.54L 38.69L 17Cr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
